Literature DB >> 1975599

Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease.

S D Solomon1, J A Jarcho, W McKenna, A Geisterfer-Lowrance, R Germain, R Salerni, J G Seidman, C E Seidman.   

Abstract

We demonstrate that familial hypertrophic cardiomyopathy (FHC), an autosomal dominant disorder of heart muscle, is a genetically heterogeneous disease. The locus responsible for FHC in members of one large kindred was recently mapped to chromosome 14q11-12 (FHC-1). We have characterized three additional unrelated families in which the gene for FHC segregates as an autosomal dominant trait to determine if these disease loci also map to FHC-1. All family members were clinically studied by physical examination, electrocardiogram, and two-dimensional echocardiography. Genetic studies were performed using DNA probes which are derived from loci that are closely linked to FHC-1. In one family the genetic defect maps to the previously identified FHC-1 locus. However, the loci responsible for FHC in two other families were not linked to FHC-1. We conclude that FHC can be caused by defects in at least two loci and is a genetically heterogeneous disorder.

Entities:  

Mesh:

Year:  1990        PMID: 1975599      PMCID: PMC296820          DOI: 10.1172/JCI114802

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  A computer program for linkage analysis of general human pedigrees.

Authors:  J Ott
Journal:  Am J Hum Genet       Date:  1976-09       Impact factor: 11.025

2.  Partial characterization of the human beta-myosin heavy-chain gene which is expressed in heart and skeletal muscle.

Authors:  P Lichter; P K Umeda; J E Levin; H P Vosberg
Journal:  Eur J Biochem       Date:  1986-10-15

3.  The genetics of hypertrophic cardiomyopathy.

Authors:  B J Maron; J J Mulvihill
Journal:  Ann Intern Med       Date:  1986-10       Impact factor: 25.391

4.  A genetic linkage map of the human genome.

Authors:  H Donis-Keller; P Green; C Helms; S Cartinhour; B Weiffenbach; K Stephens; T P Keith; D W Bowden; D R Smith; E S Lander
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

Review 5.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

6.  Linkage analysis and family classification under heterogeneity.

Authors:  J Ott
Journal:  Ann Hum Genet       Date:  1983-10       Impact factor: 1.670

7.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

Review 8.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.

Authors:  E D Wigle; Z Sasson; M A Henderson; T D Ruddy; J Fulop; H Rakowski; W G Williams
Journal:  Prog Cardiovasc Dis       Date:  1985 Jul-Aug       Impact factor: 8.194

9.  Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study.

Authors:  L M Shapiro; W J McKenna
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

10.  A locus for familial hypertrophic cardiomyopathy is closely linked to the cardiac myosin heavy chain genes, CRI-L436, and CRI-L329 on chromosome 14 at q11-q12.

Authors:  S D Solomon; A A Geisterfer-Lowrance; H P Vosberg; G Hiller; J A Jarcho; C C Morton; W O McBride; A L Mitchell; A E Bale; W J McKenna
Journal:  Am J Hum Genet       Date:  1990-09       Impact factor: 11.025

View more
  30 in total

1.  A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4.

Authors:  Lisa A Freed; James S Acierno; Daisy Dai; Maire Leyne; Jane E Marshall; Francesca Nesta; Robert A Levine; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2003-04-21       Impact factor: 11.025

2.  HLA gene analysis in a Japanese family with hypertrophic cardiomyopathy by restriction fragment length polymorphism.

Authors:  T Kanda; N Takeuchi; A Hasegawa; T Suzuki; K Murata
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

3.  No evidence for linkage of familial hypertrophic cardiomyopathy and chromosome 14q1 locus D14S26 in a Chinese family: evidence for genetic heterogeneity.

Authors:  Y L Ko; W P Lien; J J Chen; C W Wu; T K Tang; C C Liew
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

Review 4.  Progress in familial hypertrophic cardiomyopathy: molecular genetic analyses in the original family studied by Teare.

Authors:  H Watkins; C E Seidman; C MacRae; J G Seidman; W McKenna
Journal:  Br Heart J       Date:  1992-01

5.  The genetics of hypertrophic cardiomyopathy.

Authors:  D M Gilligan; J G Cleland; C M Oakley
Journal:  Br Heart J       Date:  1991-09

Review 6.  The athlete's heart: is big beautiful?

Authors:  R J Shephard
Journal:  Br J Sports Med       Date:  1996-03       Impact factor: 13.800

Review 7.  Molecular basis of hypertrophic and dilated cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  Tex Heart Inst J       Date:  1994

8.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy.

Authors:  L Fananapazir; M C Dalakas; F Cyran; G Cohn; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23.

Authors:  K R Bowles; R Gajarski; P Porter; V Goytia; L Bachinski; R Roberts; R Pignatelli; J A Towbin
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Mapping the locus for familial hypertrophic cardiomyopathy to chromosome 11 in a family with a case of apical hypertrophic cardiomyopathy of the Japanese type.

Authors:  Y L Ko; J J Chen; T K Tang; M S Teng; S Y Lin; P Kuan; C W Wu; W P Lien; C C Liew
Journal:  Hum Genet       Date:  1996-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.